Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 47 of 77 for:    "Heart Disease" | "Cobalt"

Leaders Free III: BioFreedom™ Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118895
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : September 14, 2018
Sponsor:
Collaborator:
European Cardiovascular Research Center
Information provided by (Responsible Party):
Biosensors Europe SA

Brief Summary:
A study evaluating the safety and efficacy of the BioFreedom™ Biolimus A9™ coated Cobalt Chromium coronary stent system in patients at high risk of bleeding

Condition or disease Intervention/treatment Phase
Cardiac Death Myocardial Infarction Stent Thrombosis Bleeding Mortality Device: BioFreedom™ BA9™ drug-coated stent Not Applicable

Detailed Description:
Prospective, multi-center, open-label single-arm study designed to enroll 370 HBR patients (for at least 340 evaluable) at up to 20 centers in up to 2 European countries. 370 patients will receive a BioFreedomTM CoCr stent. All patients will be followed up for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 370 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: 370 high bleeding risk items
Primary Purpose: Treatment
Official Title: A Study Evaluating the Safety and Efficacy of the BioFreedom™ Biolimus A9™ Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
Actual Study Start Date : November 8, 2017
Estimated Primary Completion Date : November 30, 2019
Estimated Study Completion Date : December 30, 2020

Arm Intervention/treatment
Experimental: Treatment Arm
Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
Device: BioFreedom™ BA9™ drug-coated stent
Drug-coated stent for coronary arteries




Primary Outcome Measures :
  1. MACE: composite of cardiac death, myocardial infarction and definite/probable stent thrombosis (safety) [ Time Frame: at 1 year ]
    Incidence

  2. clinically driven target lesion revascularization (efficacy) [ Time Frame: at 1 year ]
    incidence


Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: At 1 and 4 months, and 1 and 2 years ]
    incidence

  2. Clinically Driven Target Lesion Revascularization [ Time Frame: At 1 and 4 months, and 2 years ]
    Incidence

  3. Clinically Driven Target Vessel Revascularization [ Time Frame: At 1 and 4 months, and 2 years ]
    Incidence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   75 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients at high bleeding risk (HBR) with an indication for percutaneous coronary intervention who can tolerate no more than one month of DAPT. This includes candidates with stable angina, silent ischemia, ACS (STEMI and non-STEMI), non-native lesions and in-stent restenosis. Patients must provide written informed consent.

Reasons of unsuitability for > 1 month dual antiplatelet treatment must include one or MORE of the following:

  1. Adjunctive oral anticoagulation treatment planned to continue after PCI
  2. Age ≥ 75 years old
  3. Baseline Hgb <11 g/dl (or anemia requiring transfusion during the 4 weeks prior to inclusion into the trial)
  4. Any prior intracerebral bleed
  5. Any stroke in the last 12 months
  6. Hospital admission for bleeding during the prior 12 months
  7. Non skin cancer diagnosed or treated ≤ 3 years
  8. Planned daily NSAID (other than aspirin) or steroids for ≥ 30 days after PCI
  9. Planned surgery that would require interruption of DAPT (within next 12 months)
  10. Renal failure defined as: Creatinine clearance <40 ml/min
  11. Thrombocytopenia (PLT <100,000/mm3)
  12. Severe chronic liver disease defined as: patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice
  13. Expected non-compliance to prolonged DAPT for other medical reasons

Exclusion Criteria:

  1. Pregnant and breastfeeding women
  2. Patients expected not to comply with 1 month DAPT
  3. Patients requiring a planned staged PCI procedure more than one week after the index procedure
  4. Procedure requires the use of non-study stents, or alternative therapeutic options not followed by stent implantation (angioplasty only, atherectomy only).
  5. Active bleeding at the time of inclusion
  6. If patient requires a stent <2.5mm
  7. If patient requires a stent >3.5mm
  8. Cardiogenic shock
  9. Compliance with long-term single anti-platelet therapy unlikely
  10. Known hypersensitivity or contraindication to aspirin, clopidogrel (or to any another P2Y12 inhibitor if applicable), cobalt chromium, zinc, Biolimus A9TM or a sensitivity to contrast media, which cannot be adequately pre-medicated
  11. PCI during the previous 12 months for a lesion other than the target lesion
  12. Participation in another clinical trial (12 months after index procedure)
  13. Patients with a life expectancy of < 1 year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118895


Contacts
Layout table for location contacts
Contact: Diana Schuette +44 7970 942 022 d.schuette-consultant@biosensors.com
Contact: Dervilla Bermingham +41 798275582 d.bermingham@biosensors.com

Locations
Layout table for location information
France
at Hôpital Privé Claude Galien ICPS Recruiting
Quincy sous Sénart, Essonne, France, 91480
Contact: Philippe Garot, MD    +33.01.69.39.91.69    p.garot@angio-icps.com   
Principal Investigator: Philippe Garot, MD         
Switzerland
Triemli Stadtspital Recruiting
Zürich, Switzerland
Contact: Franz Eberli, MD       franz.eberli@triemli.zuerich.ch   
Principal Investigator: Franz Eberli, MD         
Sponsors and Collaborators
Biosensors Europe SA
European Cardiovascular Research Center
Investigators
Layout table for investigator information
Principal Investigator: Franz Eberli, Prof. Chief of Cardiology - Triemli Hospital Zurich - Switzerland
Principal Investigator: Philippe Garot, MD Hôpital Privé Claude Galien ICPS - France

Layout table for additonal information
Responsible Party: Biosensors Europe SA
ClinicalTrials.gov Identifier: NCT03118895     History of Changes
Other Study ID Numbers: 17EU01
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Infarction
Thrombosis
Infarction
Hemorrhage
Death
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Embolism and Thrombosis